Fig. 12From: Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancerComparison of the sensitivity of patients with different risk scores to common anticancer drugs. A-R Results of the IC50 of Lapatinib, Sunitinib, and Phenformin, Cal-101 (Idelalisib), Ruxolitinib, XL-184 (Cabozantinib), Sorafenib, Vinorelbine, Pyrimethamine (P < 0.001)Back to article page